Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of KRN23 in Adults with XLH (Japan/Korea)
NCT02181764Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Jul 2014
- Primary completion
- Jun 2015
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of burosumab in X-linked hypophosphatemia (XLH) (3 arms), sponsored by Kyowa Kirin. Primary endpoint: Number and types of adverse events. Started Jul 2014; status: completed.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphatemia (XLH)
Beyond the preview
Go deeper on NCT02181764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02181764.